Seems it's true the last three months haven't shown the customer growth we'd all like to see, judging a biotech company's potential purely on short-term customer acquisition might be missing the bigger picture.
Upcoming milestones like the GBA and FDA discussions could radically change the commercial landscape for OncoSil. Keep in mind that the business sectors in Israel and Spain are just a fraction of the global opportunity, especially if U.S. approvals come through. A lot can change, and quickly, in this industry. So, let's not write off the company's future based on a challenging quarter.
Pancreatic Cancer in the Media, page-59
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
-0.001(16.7%) |
Mkt cap ! $16.66M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $2.867K | 573.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 4186862 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 15328756 | 23 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| OSL (ASX) Chart |